This clinical trial is focused on studying the effects of a medication called deferiprone in children with a rare genetic disorder known as Pelizaeus-Merzbacher disease (PMD). PMD affects the nervous system and can lead to problems with movement and coordination. The medication being tested, deferiprone, is taken as an oral solution, which means it is a liquid that is swallowed.

The purpose of this study is to explore how deferiprone might help improve the ability to move in children with PMD. During the study, participants will take the medication and their progress will be monitored over time. This will involve regular check-ups and assessments to see how their motor skills, such as sitting and moving, are affected by the treatment. Some participants may receive a placebo, which looks like the medication but does not contain the active ingredient.

The study will also include various tests to gather more information about the effects of deferiprone. These tests may involve brain scans, such as MRI, and other assessments to evaluate general health, quality of life, and specific abilities like hand function and communication. The goal is to understand whether deferiprone can make a positive difference for children with PMD and to gather data that could help in developing future treatments.